Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc/ US92532F1003 /
VX1/D
|
14/11/2024 16:30:07
|
Chg.
-
|
Volume |
Bid17:30:00 |
Demandez à17:30:00 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
461.30EUR
|
-
|
66
Chiffrre d'affaires: 26,080.60 |
-Bid taille: - |
-Ask la taille: - |
113.92 Mrd.EUR |
- |
- |
Description de l'entreprise
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
Conseil d'administration & Conseil de surveillance
| PDG |
| Reshma Kewalramani, M.D. |
| Conseil d'administration |
| Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D. |
| Conseil de surveillance |
| Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay |
Données de l'entreprise
| Nom: |
Vertex Pharmaceuticals Inc. |
| Adresse: |
50 Northern Avenue,Boston, Massachusetts 02210, USA |
| Téléphone: |
+1-617-961-7163 |
| Fax: |
- |
| Courriel: |
Investorinfo@VRTX.com
|
| Internet: |
www.vrtx.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
82.70% |
| IPO date: |
24/07/1991 |
Relations avec les investisseurs
| Nom: |
Susie Lisa |
| Téléphone IR: |
+1-617-341-6108 |
| IR-Fax: |
- |
| E-mail IR: |
investorinfo@vrtx.com
|
Principaux actionnaires
| Autres |
|
53.31% |
| Vanguard Group |
|
8.63% |
| BlackRock Inc. |
|
8.48% |
| Capital World Investors |
|
8.45% |
| FMR LLC. |
|
5.03% |
| State Street Corporation |
|
4.68% |
| ALLIANCEBERNSTEIN L P |
|
2.73% |
| PRICE T ROWE ASSOCIATES INC MD |
|
2.28% |
| GEODE CAPITAL MANAGEMENT LLC |
|
2.20% |
| Autres |
|
4.21% |
